Literature DB >> 21179284

Thalidomide induced nonspecific interstitial pneumonia in patient with relapsed multiple myeloma.

Myung-Hee Kang1, Ji-Hyun Ju, Hoon-Gu Kim, Jung Hun Kang, Kyung-Nyeo Jeon, Ho-Cheol Kim, Gyeong-Won Lee.   

Abstract

A 63-year-old female diagnosed with relapsed multiple myeloma visited our hospital complaining of a persistent cough. Since July 2006, she had been taking 100 mg thalidomide daily and gradually developed shortness of breath and a persistent dry cough. A chest X-ray and computed tomography showed ground glass opacities in both lungs. An open lung biopsy of the right middle lobe under general anesthesia revealed chronic peribronchial inflammation, mild interstitial fibrosis, and intra-alveolar macrophage infiltration, with some hemosiderin features, compatible with non-specific interstitial pneumonia (NSIP). After discontinuing the thalidomide, the patient's symptoms did not deteriorate, although the radiographs did not improve. The patient is alive and well with regular outpatient follow-up without progression of the NSIP.

Entities:  

Keywords:  Lung diseases, interstitial; Multiple myeloma; Thalidomide

Mesh:

Substances:

Year:  2010        PMID: 21179284      PMCID: PMC2997975          DOI: 10.3904/kjim.2010.25.4.447

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN: 1226-3303            Impact factor:   2.884


  9 in total

1.  Thalidomide--a revival story.

Authors:  N Raje; K Anderson
Journal:  N Engl J Med       Date:  1999-11-18       Impact factor: 91.245

2.  [Lung toxicity due to thalidomide].

Authors:  F Carrión Valero; V Bertomeu González
Journal:  Arch Bronconeumol       Date:  2002-10       Impact factor: 4.872

Review 3.  Drug-induced bronchiolitis obliterans organizing pneumonia.

Authors:  Gary R Epler
Journal:  Clin Chest Med       Date:  2004-03       Impact factor: 2.878

4.  A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.

Authors:  W D Figg; W Dahut; P Duray; M Hamilton; A Tompkins; S M Steinberg; E Jones; A Premkumar; W M Linehan; M K Floeter; C C Chen; S Dixon; D R Kohler; E A Krüger; E Gubish; J M Pluda; E Reed
Journal:  Clin Cancer Res       Date:  2001-07       Impact factor: 12.531

5.  Side effects and good effects from new chemotherapeutic agents. Case 2. Thalidomide-induced interstitial pneumonitis.

Authors:  Masahiro Onozawa; Satoshi Hashino; Susumu Sogabe; Masahira Haneda; Hiromasa Horimoto; Koh Izumiyama; Takeshi Kondo; Luis Perez Aldana; Kunio Hamada; Masahiro Asaka
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

6.  Thalidomide-induced organizing pneumonia.

Authors:  Ashley A Feaver; David E McCune; Angela G Mysliwiec; Vincent Mysliwiec
Journal:  South Med J       Date:  2006-11       Impact factor: 0.954

7.  [Interstitial pneumonia during treatment with thalidomide in a patient with multiple myeloma].

Authors:  Toyotaka Iguchi; Mariyo Sakoda; Chien-kang Chen; Kenji Yokoyama; Yutaka Hattori; Yasuo Ikeda; Shinichiro Okamoto
Journal:  Rinsho Ketsueki       Date:  2004-09

8.  Pulmonary toxicity during prostate cancer treatment with docetaxel and thalidomide.

Authors:  Robert J Behrens; James L Gulley; William L Dahut
Journal:  Am J Ther       Date:  2003 May-Jun       Impact factor: 2.688

Review 9.  Interstitial lung disease associated with drug therapy.

Authors:  P Camus; S Kudoh; M Ebina
Journal:  Br J Cancer       Date:  2004-08       Impact factor: 7.640

  9 in total
  1 in total

1.  Central paradiaphragmatic middle lobe involvement in nonspecific interstitial pneumonia.

Authors:  Joanna G Escalon; Alan C Legasto; Dennis Toy; James F Gruden
Journal:  Eur Radiol       Date:  2021-02-23       Impact factor: 5.315

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.